AMARILLO BIOSCIENCES INC
10QSB, EX-27, 2000-08-03
PHARMACEUTICAL PREPARATIONS
Previous: AMARILLO BIOSCIENCES INC, 10QSB, 2000-08-03
Next: WEDGE CAPITAL MANAGEMENT L L P/NC, 13F-HR, 2000-08-03



<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONSOLIDATED BALANCE SHEET AS OF JUNE 30, 2000 AND THE CONSOLIDATED STATEMENT OF
OPERATIONS FOR THE SIX MONTHS ENDED JUNE 30, 2000 AND IS QUALIFIED IN ITS
ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS INCLUDED IN THIS FORM 10-QSB
FOR PERIOD ENDED JUNE 30, 2000.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               JUN-30-2000
<CASH>                                       1,377,180
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                     48,639
<CURRENT-ASSETS>                             1,453,631
<PP&E>                                         250,508
<DEPRECIATION>                                 150,956
<TOTAL-ASSETS>                               1,639,140
<CURRENT-LIABILITIES>                        1,252,802
<BONDS>                                      2,000,000
                                0
                                          0
<COMMON>                                        78,074
<OTHER-SE>                                 (1,691,735)
<TOTAL-LIABILITY-AND-EQUITY>               (1,639,140)
<SALES>                                              0
<TOTAL-REVENUES>                                36,128
<CGS>                                                0
<TOTAL-COSTS>                                1,873,211
<OTHER-EXPENSES>                               627,906
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              37,455
<INCOME-PRETAX>                            (2,502,444)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (2,502,444)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (2,502,444)
<EPS-BASIC>                                      (.33)
<EPS-DILUTED>                                    (.33)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission